Recursion Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Recursion Pharmaceuticals
RXRX Stock  USD 6.38  0.49  8.32%   
Recursion Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Recursion Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Recursion Pharmaceuticals financial statements helps investors assess Recursion Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Recursion Pharmaceuticals' valuation are summarized below:
Gross Profit
-164.1 M
Market Capitalization
2.5 B
Enterprise Value Revenue
33.1947
Revenue
65.2 M
Earnings Share
(1.54)
We have found one hundred twenty available trending fundamental ratios for Recursion Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Recursion Pharmaceuticals recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Recursion Pharmaceuticals Total Revenue

46.8 Million

Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 19.1 M, Interest Income of 19.2 M or Depreciation And Amortization of 25.6 M, as well as many indicators such as Price To Sales Ratio of 43.68, Dividend Yield of 0.0 or PTB Ratio of 4.64. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Recursion Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets520.4 M653.7 M253.2 M
Slightly volatile
Short and Long Term Debt Total31.9 M50.7 M21.5 M
Slightly volatile
Other Current Liabilities27.4 M40.5 M13 M
Slightly volatile
Total Current Liabilities59.4 M93.2 M26 M
Slightly volatile
Other Liabilities84.8 M80.8 M19.3 M
Slightly volatile
Property Plant And Equipment Net78.5 M120.2 M43.6 M
Slightly volatile
Accounts Payable3 M4 M1.9 M
Slightly volatile
Cash342.9 M391.6 M168.7 M
Slightly volatile
Non Current Assets Total226.3 M215.6 M61.9 M
Slightly volatile
Non Currrent Assets Other5.5 M6.9 M2.4 M
Slightly volatile
Other Assets0.951.01.6 M
Slightly volatile
Long Term Debt1 M1.1 M9.3 M
Slightly volatile
Cash And Short Term Investments393.8 M391.6 M187.5 M
Slightly volatile
Net Receivables3.4 M3.1 M1.3 M
Slightly volatile
Common Stock Shares Outstanding194.8 M207.9 M171.5 M
Slightly volatile
Liabilities And Stockholders Equity520.4 M653.7 M253.2 M
Slightly volatile
Non Current Liabilities Total149.4 M97.1 M203.6 M
Pretty Stable
Capital Lease Obligations25.9 M49.5 M11.8 M
Slightly volatile
Other Current Assets45.7 M43.5 M8.6 M
Slightly volatile
Total Liabilities192.6 M190.3 M228.5 M
Very volatile
Property Plant And Equipment Gross92.5 M165 M48.8 M
Slightly volatile
Short and Long Term Debt39 K41 K140.7 K
Pretty Stable
Total Current Assets415.5 M438.1 M199.4 M
Slightly volatile
Net Working Capital356.1 M345 M173.5 M
Slightly volatile
Short Term Debt6.2 M12.3 M2.6 M
Slightly volatile
Property Plant Equipment146.6 M139.7 M49.5 M
Slightly volatile
Current Deferred Revenue31.1 M36.4 M16.3 M
Slightly volatile
Good Will54.7 M52.1 M7.8 M
Slightly volatile
Intangible Assets38.3 M36.4 M7 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Long Term Debt Total506.4 K569.7 K620.3 K
Slightly volatile
Capital Surpluse754.5 M848.8 M924.3 M
Slightly volatile
Deferred Long Term Liabilities3.3 M3.7 M4 M
Slightly volatile
Non Current Liabilities Other12.8 M14.4 M15.7 M
Slightly volatile
Common Stock1.6 K1.8 K2 K
Slightly volatile

Recursion Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income19.2 M18.3 M4.1 M
Slightly volatile
Depreciation And Amortization25.6 M24.4 M7.8 M
Slightly volatile
Interest Expense92.2 K97 K727.1 K
Very volatile
Selling General Administrative64.7 M110.8 M35.3 M
Slightly volatile
Total Revenue46.8 M44.6 M10.8 M
Slightly volatile
Other Operating Expenses225.5 M394.6 M121.9 M
Slightly volatile
Research Development141.1 M241.2 M79.6 M
Slightly volatile
Cost Of Revenue33.5 M42.6 M43.7 M
Pretty Stable
Total Operating Expenses205.5 M352 M114.5 M
Slightly volatile
Reconciled Depreciation10.6 M20.1 M6 M
Slightly volatile
Selling And Marketing Expenses8.3 M9.4 M10.2 M
Slightly volatile

Recursion Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation56.2 M53.5 M11.4 M
Slightly volatile
Begin Period Cash Flow587.1 M559.1 M129.4 M
Slightly volatile
Other Cashflows From Financing Activities12.2 M12.8 M26.9 M
Pretty Stable
Depreciation25.6 M24.4 M6.6 M
Slightly volatile
Capital Expenditures21.9 M12 M10.5 M
Slightly volatile
Issuance Of Capital Stock255.1 M193.7 M166.2 M
Slightly volatile
Total Cash From Financing Activities179.1 M140.1 M158.8 M
Slightly volatile
End Period Cash Flow351.6 M401.4 M175.1 M
Slightly volatile
Other Cashflows From Investing Activities476 K535.5 K583.1 K
Slightly volatile
Change To Netincome47.4 M45.2 M11.5 M
Slightly volatile
Change To Inventory1.7 K1.8 K3.7 M
Slightly volatile
Sale Purchase Of Stock377.1 M424.2 M461.9 M
Slightly volatile
Change Receivables91.2 K102.6 K111.7 K
Slightly volatile
Cash And Cash Equivalents Changes22.5 M25.4 M27.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio43.6845.97731.2 K
Slightly volatile
Days Sales Outstanding24.0725.335149.6879
Pretty Stable
Stock Based Compensation To Revenue0.871.20030.9073
Slightly volatile
Capex To Depreciation0.470.48991.7399
Very volatile
EV To Sales36.4138.32971.2 K
Slightly volatile
Inventory Turnover35.6433.9414.1567
Slightly volatile
Days Of Inventory On Hand10.5711.1336.2667
Slightly volatile
Payables Turnover10.2310.773330.4661
Slightly volatile
Sales General And Administrative To Revenue2.362.48628.7221
Slightly volatile
Research And Ddevelopement To Revenue5.145.411720.9525
Slightly volatile
Capex To Revenue0.250.26822.0177
Slightly volatile
Cash Per Share1.611.88381.0304
Slightly volatile
Days Payables Outstanding31.6533.879921.326
Slightly volatile
Income Quality0.770.87720.8391
Slightly volatile
Intangibles To Total Assets0.140.13540.0249
Slightly volatile
Net Debt To EBITDA1.951.1381.2715
Slightly volatile
Current Ratio4.474.702510.1521
Slightly volatile
Receivables Turnover13.8914.406911.9333
Pretty Stable
Graham Number5.38.89834.0765
Slightly volatile
Capex Per Share0.0880.05750.0579
Slightly volatile
Revenue Per Share0.230.21450.0569
Slightly volatile
Interest Debt Per Share0.05910.03540.0694
Slightly volatile
Debt To Assets0.01050.01110.0873
Slightly volatile
Operating Cycle24.0725.335184.5079
Very volatile
Days Of Payables Outstanding31.6533.879921.326
Slightly volatile
Ebt Per Ebit1.090.94880.9981
Slightly volatile
Quick Ratio4.474.70259.6071
Slightly volatile
Net Income Per E B T1.090.98781.0098
Very volatile
Cash Ratio8.274.20269.3312
Slightly volatile
Days Of Inventory Outstanding10.5711.1336.2667
Slightly volatile
Days Of Sales Outstanding24.0725.335149.6879
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.951.04361.1017
Pretty Stable
Fixed Asset Turnover0.390.37090.1384
Slightly volatile
Debt Ratio0.01050.01110.0873
Slightly volatile
Price Sales Ratio43.6845.97731.2 K
Slightly volatile
Asset Turnover0.07160.06820.0262
Slightly volatile

Recursion Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2 B2.7 B
Slightly volatile
Enterprise Value1.9 B1.7 B2.4 B
Slightly volatile

Recursion Fundamental Market Drivers

Cash And Short Term Investments391.6 M

Recursion Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue36.4 M31.1 M
Total Revenue44.6 M46.8 M
Cost Of Revenue42.6 M33.5 M
Stock Based Compensation To Revenue 1.20  0.87 
Sales General And Administrative To Revenue 2.49  2.36 
Research And Ddevelopement To Revenue 5.41  5.14 
Capex To Revenue 0.27  0.25 
Revenue Per Share 0.21  0.23 
Ebit Per Revenue(7.85)(8.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY